These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 33773120)

  • 21. Riociguat for pulmonary arterial hypertension associated with congenital heart disease.
    Rosenkranz S; Ghofrani HA; Beghetti M; Ivy D; Frey R; Fritsch A; Weimann G; Saleh S; Apitz C
    Heart; 2015 Nov; 101(22):1792-9. PubMed ID: 26135803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular-Pulmonary Arterial Coupling.
    Taran IN; Belevskaya AA; Saidova MA; Martynyuk TV; Chazova IE
    Lung; 2018 Dec; 196(6):745-753. PubMed ID: 30182153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE.
    Benza RL; Corris PA; Klinger JR; Langleben D; Naeije R; Simonneau G; Ghofrani HA; Jansa P; Rosenkranz S; Scelsi L; Thenappan T; Raina A; Meier C; Busse D; Hoeper MM
    Int J Cardiol; 2020 Oct; 317():188-192. PubMed ID: 32461118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.
    Humbert M; Coghlan JG; Ghofrani HA; Grimminger F; He JG; Riemekasten G; Vizza CD; Boeckenhoff A; Meier C; de Oliveira Pena J; Denton CP
    Ann Rheum Dis; 2017 Feb; 76(2):422-426. PubMed ID: 27457511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
    Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Rosenkranz S; Feldman J; McLaughlin VV; Rischard F; Lange TJ; White RJ; Peacock AJ; Gerhardt F; Ebrahimi R; Brooks G; Satler C; Frantz RP;
    Lancet Respir Med; 2022 Jan; 10(1):35-46. PubMed ID: 34425071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
    Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
    J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
    Ghofrani HA; D'Armini AM; Grimminger F; Hoeper MM; Jansa P; Kim NH; Mayer E; Simonneau G; Wilkins MR; Fritsch A; Neuser D; Weimann G; Wang C;
    N Engl J Med; 2013 Jul; 369(4):319-29. PubMed ID: 23883377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
    Chin KM; Sitbon O; Doelberg M; Feldman J; Gibbs JSR; Grünig E; Hoeper MM; Martin N; Mathai SC; McLaughlin VV; Perchenet L; Poch D; Saggar R; Simonneau G; Galiè N
    J Am Coll Cardiol; 2021 Oct; 78(14):1393-1403. PubMed ID: 34593120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Riociguat: Clinical research and evolving role in therapy.
    Klinger JR; Chakinala MM; Langleben D; Rosenkranz S; Sitbon O
    Br J Clin Pharmacol; 2021 Jul; 87(7):2645-2662. PubMed ID: 33242341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial.
    Frantz RP; McLaughlin VV; Sahay S; Escribano Subías P; Zolty RL; Benza RL; Channick RN; Chin KM; Hemnes AR; Howard LS; Sitbon O; Vachiéry JL; Zamanian RT; Cravets M; Roscigno RF; Mottola D; Osterhout R; Bruey JM; Elman E; Tompkins CA; Parsley E; Aranda R; Zisman LS; Ghofrani HA;
    Lancet Respir Med; 2024 Jul; 12(7):523-534. PubMed ID: 38705167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
    Prescrire Int; 2015 Nov; 24(165):265-6. PubMed ID: 26688897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.
    Baughman RP; Shlobin OA; Gupta R; Engel PJ; Stewart JI; Lower EE; Rahaghi FF; Zeigler J; Nathan SD
    Chest; 2022 Feb; 161(2):448-457. PubMed ID: 34363816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial.
    Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M
    Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 40. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
    Distler O; Allanore Y; Denton CP; Kuwana M; Matucci-Cerinic M; Pope JE; Atsumi T; Bečvář R; Czirják L; Hachulla E; Ishii T; Ishikawa O; Johnson SR; De Langhe E; Stagnaro C; Riccieri V; Schiopu E; Silver RM; Smith V; Steen V; Stevens W; Szücs G; Truchetet ME; Wosnitza M; Laapas K; Kramer F; Khanna D
    Lancet Rheumatol; 2023 Nov; 5(11):e660-e669. PubMed ID: 38251533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.